Keyphrases
Neural Stem Cells
100%
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
Anti-human Epidermal Growth Factor Receptor 2
100%
Tucatinib
100%
Metastatic Brain Cancer
100%
Breast Cancer Brain Metastasis
71%
Patients with Breast Cancer
28%
Intracranial Metastases
28%
Clinical Trials
14%
Monoclonal Antibody
14%
Clinically Significant
14%
Therapeutic Potential
14%
Improved Outcomes
14%
Leading Causes of Death
14%
Blood-brain Barrier
14%
Overexpression
14%
Brain Metastases
14%
Brain Tumor
14%
Targeted Therapy
14%
Breast Cancer Patients
14%
Metastatic Breast Cancer
14%
Tumor Cell Proliferation
14%
Targeted Agents
14%
Tropics
14%
Trastuzumab
14%
PI3K-Akt Pathway
14%
Significant Benefit
14%
Stemness
14%
Therapeutic Regimen
14%
Xenograft Model
14%
Intracranial Xenografts
14%
Human Neural Stem Cells (hNSCs)
14%
Tyrosine Kinase Inhibitor
14%
Proliferation in Vitro
14%
Multiple Persons
14%
Pertuzumab
14%
Highly Migratory Species
14%
Full-length Antibodies
14%
Medicine and Dentistry
Breast Cancer
100%
Brain Cancer
100%
Gamma Urogastrone
100%
Epidermal Growth Factor Receptor 2
100%
Neural Stem Cell
100%
Tucatinib
100%
Brain Metastasis
75%
Metastatic Carcinoma
25%
In Vitro
12%
Intracranial Tumor
12%
Xenograft
12%
Tumor Cell
12%
Cell Proliferation
12%
Blood Brain Barrier
12%
Tyrosine-Kinase Inhibitor
12%
Akt Signaling
12%
Clinical Trial
12%
Targeted Therapy
12%
Signal Transduction
12%
Monoclonal Antibody
12%
Trastuzumab
12%
Pertuzumab
12%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Brain Cancer
100%
Epidermal Growth Factor Receptor 2
100%
Gamma Urogastrone
100%
Tucatinib
100%
Brain Metastasis
75%
Clinical Trial
12%
Protein Tyrosine Kinase Inhibitor
12%
Intracranial Tumor
12%
Neoplasm
12%
Monoclonal Antibody
12%
Trastuzumab
12%
Pertuzumab
12%
Blood-Brain Barrier
12%
Immunology and Microbiology
Gamma Urogastrone
100%
Neural Stem Cell
100%
Immunology
100%
Xenograft
12%
Cell Proliferation
12%
Tumor Cell
12%
Monoclonal Antibody
12%
Blood Brain Barrier
12%
Akt Signaling
12%
Pertuzumab
12%
Trastuzumab
12%
Signal Transduction
12%